Anna Westlind-Johnsson

Dr Anna Westlind-Johnsson joins ApconiX as a Project Toxicologist in Regulatory Toxicology within the Toxicology and DMPK Consultancy Team. With more than 15 years of experience at AstraZeneca, Anna delivers toxicology support to clients' drug projects, provides strategic and pragmatic advice, plans and executes toxicology programs, and supports health authority interactions. She has contributed to multiple health authority interactions in several territories including FDA, EMA, MHRA and PMDA. Her experience also includes senior roles at Swedish health authorities, giving her a unique perspective on benefit-risk assessment. 

Read more about Anna Westlind-Johnsson

Yvonne Will

Read more about Yvonne Will

Andrew Fleetwood

PhD

Andrew Fleetwood joins our Toxicology and DMPK Consultancy Team as a Toxicology specialist, working closely with Dr Richard Knight to support clients in late-stage medicine development. He brings extensive expertise in non-clinical regulatory toxicology, including preparation of regulatory submissions, responses to health authority questions, and post-authorisation activities. His background leading non-clinical regulatory strategy at Pfizer strengthens ApconiX’s capabilities in regulatory compliance, risk assessment, and late-phase development strategy. Andrew also adds specialist knowledge in impurities and extractables and leachables, helping clients plan qualification strategies and manage manufacturing and packaging risks.

Read more here

Andreas Hartmann

PhD

Andreas Hartmann joined the Toxicology and DMPK Consultancy Team as an associate non-clinical safety specialist, advising project teams, defining toxicology strategies, and supporting regulatory interactions. He brings extensive leadership experience from his past role, where he led global preclinical safety teams delivering non-clinical programmes from target identification through post-marketing across multiple therapeutic areas and drug modalities. His background in genetic toxicology, impurities safety, and complex regulatory submissions significantly strengthens our non-clinical safety offering. Andreas also adds strong regulatory and industry-facing expertise, including engagement with regulators on high-profile safety topics.

Read more here

Ken Page

MSc

Ken has worked in the pharmaceutical industry, both in large companies (Astra Zeneca and Rhône Poulenc [now Sanofi]), small biotech (RedX), and CROs for many decades. During this time, Ken has either managed or been part of many teams including bioanalysis, P450 inhibition, in vitro permeability, metabolic stability, ADME, in vivo pharmacokinetics & PK modelling, helping identify new drugs effective in several disease areas including Oncology, Cardiovascular, Asthma & Inflammation and Anti-bacterial agents. Ken has a keen interest in human PK prediction and using it as early as possible to identify potential drug candidates. Ken has a BSc in Biochemistry and an MSc degree in Biopharmacy.

Read more here

Olga King

PhD

Dr Olga King is joining the Project Toxicology Team at ApconiX and will be designing and reviewing nonclinical toxicology studies among other responsibilities. Olga has a PhD in Veterinary Toxicology & Pharmacology from Ulyanovsk Agricultural University in Russia. Olga has previously worked as a Study Director at Sequani and LabCorp. She is a curious scientist who is looking forward to using her veterinary background and diverse study director experience in her new role.

Read more here

Peggy Guzzie-Peck

MS PhD DABT

Peggy has over 30 years’ experience working in various global scientific and management roles in nonclinical toxicology at large pharmaceutical companies (Pfizer, Johnson & Johnson and G.D. Searle).  Previous roles included Global Head, Toxicology, Pathology, Head of Preclinical Investigative Safety Sciences and Global Head, Genetic Toxicology.  Peggy graduated from the University of Pittsburgh and is now based in Florida.  Peggy is a long-standing diplomate of the American Board of Toxicology with a diverse background over all pharmaceutical therapeutic areas, predominantly specialising in small molecules and more recently in Cell/Gene therapies.

Susan Tantawi

DABT

Based in Montreal in Canada, Susan has over fifteen years’ experience working in CROs, consultancies and biotechnology companies.  With broad toxicology expertise, Susan also has specialist knowledge of inhalation toxicity. Always keen to support the progress of a compound to the next stage, she particularly enjoys the structured organisation involved in timelines and gap analysis.  Susan is a board certified toxicologist.

Jo Kilgour

PhD

Jo Kilgour is an expert Inhalation Toxicologist, having worked in the field for 30 years, initially working in the agrochemicals and chemicals sector at Central Toxicology Laboratory as a Study Director and Project Toxicologist, and for the last 20 years working almost exclusively in inhaled drug development, formerly at AstraZeneca.

Jo works with small and large Pharma companies worldwide to deliver toxicology programs for small molecules and biologics to support First in Human studies (Phase 1) through to Phase 3 clinical trials and registration. She has represented clients in interactions with Regulators in Europe and the US, and worked on drugs (small and large molecule) targeting many therapeutic areas including COPD, asthma, cystic fibrosis, idiopathic pulmonary fibrosis and anti-virals.

Jo has been an active member of the British Toxicology Society and the Association of Inhalation Toxicologists, Chairing the latter since 2011. She has co-authored a number of pivotal papers under the banner of the AIT and Industry Consortia, and has been an invited expert speaker at a number institutions and events including the US FDA, the European Chemicals Agency (EChA) and the University of Birmingham.

Haroon Rashid

PhD

Haroon has over 14 years of experience as a CRO study director, senior study director and toxicologist. He managed numerous investigative and regulatory toxicity studies for small molecules and biologicals in general and developmental and reproductive toxicology. He was involved in advising clients about their preclinical programmes, study design and execution, data interpretation and reporting for regulatory submission. Haroon brings his problem-solving skills and collaborative approach to the delivery of projects in an effective and timely manner.

Read more here Haroon Rashid